Abstract
Asthma is increasingly recognised as a heterogeneous group of diseases with similar clinical presentations rather than a singular disease entity. Asthma was historically categorised by clinical symptoms; however, newer methods of subgrouping, describing and categorising the disease have sub-defined asthma. These sub-definitions are intermittently called phenotypes or endotypes, but the real meanings of these words are poorly understood. Novel treatments are currently and increasingly available, partly in the monoclonal antibody environment, and also some physical therapies (bronchial thermoplasty), but additionally small molecules are not far away from clinical practice. Understanding the disease pathogenesis and the mechanism of action more completely may enable identification of treatable traits, biomarkers, mediators and modifiable therapeutic targets. However, there remains a danger that clinicians become preoccupied with the concept of endotypes and biomarkers, ignoring therapies that are hugely effective but have no companion biomarker. This review discusses our understanding of the concept of phenotypes and endotypes in appreciating and managing the heterogeneous condition that is asthma. We consider the role of functional imaging, physiology, blood-, sputum- and breath-based biomarkers and clinical manifestations that could be used to produce a personalised asthma profile, with implications on prognosis, pathophysiology and most importantly specific therapeutic responses. With the advent of increasing numbers of biological therapies and other interventional options such as bronchial thermoplasty, the importance of targeting expensive therapies to patients with the best chance of clinical response has huge health economic importance.
Similar content being viewed by others
References
British Thoracic Society, Scottish Intercollegiate Guidance Network. British guideline on the management of asthma: a national clinical guideline. 2016. http://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016 Accessed 08 Oct 2016.
Kiley J, Smith R, Noel P. Asthma phenotypes. Curr Opin Pulm Med. 2007;13(1):19–23.
Bel EH. Clinical phenotypes of asthma. Curr Opin Pulm Med. 2004;10(1):44–50.
Hekking PPW, Bel EH. Developing and emerging clinical asthma phenotypes. J Allergy Clin Immunol. 2014;2(6):671–80.
Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Brit Med Bull. 2000;56(4):1054–70.
Lötvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol. 2011;127(2):355–60.
Wesolowska-Anderson A, Seibold MA. Airway molecular endotypes of asthma: dissecting the heterogeneity. Curr Opin Allergy Clin Immunol. 2015;15(2):163–8.
George BJ, Reif DM, Gallagher JE, et al. Data-driven asthma endotypes defined from blood biomarker and gene expression data. PLoS One. 2015;10(2):e0117445. doi:10.1371/journal.pone.0117445.
Agache I, Akdis C, Jutel M, et al. Untangling asthma phenotypes and endotypes. Allergy. 2012;67(7):835–46.
Rajan JP, Wineinger NE, Stevenson DD, et al. Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: a meta-analysis of the literature. J Allergy Clin Immunol. 2015;135(3):676–81.
Denning DW, O’Driscoll BR, Hogaboam CM, et al. The link between fungi and severe asthma: a summary of the evidence. Eur Respir J. 2006;27:615–26.
Farrant J, Brice H, Fowler S. Fungal sensitisation in severe asthma is associated with the identification of Aspergillus fumigatus in sputum. J Asthma. 2016;53(7):732–5.
Meyer N, Dallinga JW, Nuss S, et al. Defining adult asthma endotypes by clinical features and patterns of volatile organic compounds in exhaled air. Resp Res. 2014;15:136.
Denning DW, O’Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med. 2009;179(1):11–8.
Castro-Rodriguez JA, Holberg CJ, Wright AL, et al. A clinical index to define risk of asthma in young children with recurrent wheezing. Am J Respir Crit Care Med. 2000;162:1403–6.
Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy. 2014;7:53–65.
Nair P, Pizzichini MMM, Kjarsgaard M, et al. Mepolizumab for prednisolone-dependant asthma with sputum eosinophilia. N Engl J Med. 2009;360:985–93.
Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Resp Med. 2015;3(5):355–66.
Fitzgerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016. doi:10.1016/S0140-6736(16)31322-8.
Wenzel S, Castro M, Coreen J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high dose inhaled corticosteroids pus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44.
Brightling CE, Chanez P, Leigh R, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Resp Med. 2015;3(9):692–701.
Gonem S, Berair R, Singapuri, et al. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. Lancet. 2016;4(9):699–707.
Helenius I, Lumme A, Haahtela T. Asthma, airway inflammation and treatment in elite athletes. Sports Med. 2005;35(7):565–74.
Sestini P, Armetti L, Gambaro G, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med. 1996;153(2):572–5.
Picado C, Fernandez-Morata JC, Juan M, et al. Cyclooxygenase-2 mRNA is down expressed in nasal polyps from aspirin-sensitive asthmatics. Am J Respir Crit Care Med. 1999;160:291–6.
Szczeklsik A, Mastalerz L, Nizankowska E, et al. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med. 1996;153(2):567–71.
Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J. 1993;6:391–9.
Christie PE, Tagari P, Ford-Hutchinson AW, et al. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis. 1991;143(5Pt1):1025–9.
Cowburn AS, Krzysztof S, Soja J, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Investig. 1998;101(4):834–46.
Steinke JW, Borish L. Factors driving the aspirin exacerbated respiratory disease phenotype. Am J Rhinol Allergy. 2015;29(1):35–40.
Jinnai N, Sakagami T, Sekigawa T, et al. Polymorphisms in the prostaglandin E2 receptor subtype 2 gene confer susceptibility to aspirin-intolerant asthma: a candidate gene approach. Hum Mol Genet. 2004;13(24):3203–17.
Liu T, Laidlaw TM, Katz HR, et al. Prostaglandin E2 deficiency causes and phenotype of aspirin sensitivity that depends on platelets and cysteinyl leukotrienes. P Natl Acad Sci Biol. 2013;110(42):16987–92.
Kim S-H, Oh J-M, Kim Y-S, et al. Cysteinyl leukotriene receptor 1 promoter polymorphism is associated with aspirin-intolerant asthma in males. Clin Exp Allergy. 2006;36:433–9.
Laidlaw TM, Boyce JA. Pathogenesis of aspirin-exacerbated respiratory disease and reactions. Immunol Allergy Clin North Am. 2013;33(2):195–210.
Izuhara K, Ohta S, Ono J. Using periostin as a biomarker in the treatment of asthma. Allergy Asthma Immunol Res. 2016;8(6):491–8.
Steinke JW, Wilson JM. Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances. J Asthma Allergy. 2016;9:37–43.
Levy JM, Rudmik L, Peters AT, et al. Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease: an evidence-based review with recommendations. Int Forum Allergy Rhinol. 2016;6(12):1273–83.
Knutsen AP, Slavin RG. Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis. Clin Dev Immunol. 2011;843763:1–14.
Hogan C, Denning DW. Allergic bronchopulmonary aspergillosis and related allergic syndromes. Semin Respir Crit Care Med. 2011;32(6):682–92.
Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013;43:850–73.
Vincenzo AG, Chupp GL, Tsirilakis K, et al. CHIT1 mutations: genetic risk factor for severe asthma with fungal sensitization? Pediatrics. 2010;126(4):e982–5.
Vaid M, Kaur S, Sambatakou H, et al. Distinct alleles of mannose binding lectin (MBL) and surfactant proteins A (SP-A) in patients with chronic cavitatory pulmonary aspergillosis and allergic bronchopulmonary aspergillosis. Clin Chem Lab Med. 2007;45(2):183–6.
Carvalho A, Pasqualotto AC, Pitzurra L, et al. Polymorphisms in toll-like receptor genes and susceptibility to pulmonary aspergillosis. J Infect Dis. 2008;197(4):618–21.
Agarwal R, Khan A, Aggarwal AN, et al. Link between CFTR mutations and ABPA: a systematic review and meta-analysis. Mycoses. 2012;55(4):357–65.
Chauhan B, Santiago L, Hutcheson PS, et al. Evidence for the involvement of two different MHC class II regions in susceptibility of protection in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2000;106(4):723–9.
Knutsen AP, Kariuki B, Concolino JD, et al. IL-4 alpha chain receptor (IL-4Rα) polymorphisms in allergic bronchopulmonary aspergillosis. Clin Mol Allergy. 2006;4(1):1–4.
Godet C, Goudet V, Laurent F, et al. Nebulised liposomal amphotericin B for Aspergillus lung diseases: case series and literature review. Mycoses. 2015;58:173–80.
Chishimba L, Landridge P, Powell G, et al. Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). J Asthma. 2015;52(3):289–95.
Voskamp AL, Gillman A, Symons K, et al. Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol: In Practice. 2015;3(2):192–9.
Possa S, Leick EA, Prado CM, et al. Eosinophilic inflammation in allergic asthma. Front Pharmacol. 2013;4:46. doi:10.3389/fphar.2013.00046.
Brightline CE. Eosinophils, bronchitis and asthma: pathogenesis of cough and airflow obstructions. Pulm Pharmacol Ther. 2011;24:324–7.
Lemanske RF Jr, Busse WW. Asthma: clinical expression and molecular mechanisms. J Allergy Clin Immunol. 2010;125:S95–102.
Kim Y-M, Kim Y-S, Jeon SG, et al. Immunopathogenesis of allergic asthma: more than the th2 hypothesis. Allergy Asthma Immunol Res. 2013;5(4):189–96.
Kolsum U, Donaldson GC, Singh R, et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir Res. 2017;18:88. doi:10.1186/s12931-017-0570-5.
Slager RE, Li H, Moore W, et al. Predictive model of severe atopic asthma phenotypes using interleukin 4/13 pathway polymorphisms. In: American Thoracic Society International Conference. A33. Genetic and Epigenetic Regulation of Lung Disease. 2011, A1332.
Moffatt MF, Kabesch M, Liang L, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature. 2007;448:470–3.
Andiappan AK, Sio YY, Lee B, et al. Functional variants of 17q12-21 are associated with allergic asthma but not allergic rhinitis. J Allergy Clin Immunol. 2016;137(3):758–66.
Michel S, Busato F, Genuneit J, et al. Farm exposure and time trends in early childhood may influence DNA methylation in genes related to asthma and allergy. Allergy. 2013;68(3):355–64.
Klaassen EMM, Penders J, Jöbsis Q, et al. An ADAM33 polymorphisms associated with progression of preschool wheeze into childhood asthma: a prospective case control study with replication in a birth cohort study. PLoS One. 2015;10(3):e0119349.
Holgate ST, Davies DE, Murphy G, et al. ADAM33: just another asthma gene or a breakthrough in understanding the origins of bronchial hyperresponsiveness? Thorax. 2003;58(6):466–9.
Durham AL, Caramoiri G, Chung KF, et al. Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. Transl Res. 2016;167(1):192–203.
Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Resp J. 2014;43:343–73.
D’Hooghe JNS, De Bruin DM, Wijmans L, et al. Bronchial wall thickness assessed by optical coherence tomography (OCT) before and after bronchial thermoplasty (BT). Eur Respir J. 2015;46(59):OA1763.
Salam MT, Wenten M, Gilliland FD. Endogenous sex steroid hormones and asthma and wheeze in young women. J allergy Clin Immunol. 2006;117(5):100–7.
Troisi RJ, Speizer FE, Willett WC, et al. Menopause, postmenopausal estrogen preparations and the risk of adult-onset asthma. A prospective cohort study. Am J Crit Care Med. 1995;152(4):1183–8.
Nahm D-H, Lee K-H, Shin J-Y, et al. Identification of α-enolase as an autoantigen associated with severe asthma. J Allergy Clin Immunol. 2006;118(2):376–81.
Nahm D-H, Lee Y-E, Yim E-J, et al. Identification of cytokeratin 18 as a bronchial epithelial autoantigen associated with nonallergic asthma. Am J Respir Crit Care Med. 2002;165(11):1536–9.
Hizawa N, Yamaguchi E, Konno S, et al. A functional polymorphism in the RANTES gene promoter is associated with the development of late-onset asthma. Am J Resp Crit Care Med. 2002;166(5):686–90.
Taniguchi N, Konno S, Hattori T, et al. The CC16 A38G polymorphism is associated with asymptomatic airway hyper-responsiveness and development of late-onset asthma. Ann Allergy Asthma Immunol. 2013;111(5):376–81.
Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716–25.
Coleman JM, Naik C, Holguin F, et al. Epithelial eotaxin-2 and eotaxin-3 expression: relation to asthma severity, luminal eosinophilia and age of onset. Thorax. 2012;201634:1–6.
Labrador-Horillo M, Ramentol M, Martinez-Valle F, et al. Eotaxin is overexpressed in Churg-Strauss syndrome compared to allergic asthma. Ann Rheum Dis. 2013;72:A800.
Schwartz LB, Delgado L, Craig T, et al. Exercise-induced hypersensitivity syndromes in recreational and competitive athletes: a PRACTALL consensus report (what the general practitioner should know about sports and allergy). Allergy. 2008;63(8):953–61.
Karjalainen EM, Laitinen A, Sue-Chu M, et al. Evidence of airway inflammation and remodelling in ski athletes with and without bronchial hyperresponsiveness to methacholine. Am J Respir Crit Care Med. 2000;161:2086–91.
Carlsen KH. Mechanism of asthma development in elite athletes. Breathe. 2012;8(4):279–84.
Carlsen KH, Anderson SD, Bjermer L, et al. Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part 1 of the report from the joint task force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN. Allergy. 2008;63(4):387–403.
Hallstrand TS, Moody MW, Wurfel MM, et al. Inflammatory basis of exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 2005;172(6):679–86.
Bougault V, Turmel J, St-Laurent J, et al. Asthma, airway inflammation and epithelial damage in swimmers and cold air athletes. Eur Respir J. 2009;33:740–6.
Chimenti L, Morici G, Paternò A, et al. Bronchial epithelial damage after a half-marathon in nonasthmatic amateur runners. Am J Physiol Lung C. 2010;298(6):L857–62.
Carlsen KH. Sports in extreme conditions: the impact of exercise in cold temperatures on asthma and bronchial hyper-responsiveness in athletes. Brit J Sport Med. 2012;46:796–9.
Pelaia G, Vatrella A, Busceti MT, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediat Inflamm. 2015;879783:1–8.
Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J. 2013;41:716–26.
Newcomb DC, Stokes-Peebles R Jr. Th17-mediated inflammation in asthma. Curr Opin Immunol. 2013;25(6):1–12.
Al-ramil W, Préfontaine D, Chouiali F, et al. Th17-associated cytokines (IL-17A and IL-17F) in severe asthma. J Allergy Clin Immunol. 2009;123(5):1185–7.
Yang XO, Chang SH, Park H, et al. Regulation of inflammatory responses by IL-17F. J Exp Med. 2008;205(5):1063–75.
Hoskins A, Reiss S, Wu P, et al. Asthmatic airway neutrophilia after allergen challenge is associated with the glutathione S-transferase M1 genotype. Am J Resp Crit Care Med. 2013;187(1):34–41.
Kawaguchi M, Takahashi D, Hizawa N, et al. IL-17F sequence variant (HI161Arg) is associated with protection against asthma and antagonizes wild-type IL-17F activity. J Allergy Clin Immunol. 2006;117(4):795–801.
Desai D, Gupta S, Siddiqui S, et al. Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma. Resp Res. 2013;14(17):1–13.
Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2008;177(2):148–55.
Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomised placebo-controlled clinical trial. Clin Exp Allergy. 2012;42(7):1097–103.
Bruijnzeel PLB, Uddin M, Koenderman L. Targeting neutrophilic inflammation in severe neutrophilic asthma: can we target the disease-relevant neutrophil phenotype? J Leukocyte Biol. 2015;98(4):549–56.
Meyer N, Dallinga JW, Nuss S, et al. Defining adult asthma endotypes by clinical features and patterns of volatile organic compounds in exhaled air. Resp Res. 2014;15:136.
Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Resp Crit Care Med. 2010;181(4):315–23.
Moore WC, Li X, Li H, et al. Clinical cluster phenotypes from the Severe Asthma Research Program (SARP1/2): reproducibility in SARP 3 and the importance of baseline lung function in disease stability and progression. Am J Respir Crit Care Med. 2016;193:A7852.
Wu W, Bleecker ER, Meyers DA, et al. Differential response to systemic corticosteroids as assessed by cluster analysis of data from the Severe Asthma Research Program (SARP). Am J Respir Crit Care Med. 2017;195:A1362.
Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–24.
Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Car Med. 2010;181:315–23.
Hastie A, Mauger D, Denlinger LC, et al. Sputum and blood eosinophil and neutrophil associations with a more severe asthma phenotype in the NHLBI Severe Asthma Research Program (SARP). Am J Respir Crit Care Med. 2017;195:A4695.
Schatz M, Hsu JWY, Zeiger RS. Phenotypes determined by cluster analysis in severe or difficult-to-treat asthma. J Allergy Clin Immunol. 2014;133:1549–56.
Ortega H, Li H, Suruki R. Cluster analysis and characterisation of response to mepolizumab: a step closer to personalised medicine for patients with severe asthma. Ann Am Thorac Soc. 2014;11(7):1011–7.
Thien F. Measuring and imaging small airways dysfunction in asthma. Asia Pac Allergy. 2013;3(4):224–30.
Zhang WJ, Niven RM, Young SS, et al. Dynamic oxygen-enhanced magnetic resonance imaging of the lung in asthma—initial experience. Eur J Radiol. 2015;84:318–26.
Aysola R, de Lange EE, Castro M, et al. Demonstration of the heterogeneous distribution of asthma in the lungs using CT and hyperpolarized helium-3 MRI. J Magn Reson Imaging. 2010;32(6):1379–87.
Thomen RP, Sheshadri A, Quirk JD, et al. Regional ventilation changes in severe asthma after bronchial thermoplasty with 3He MR imaging and CT. Radiology. 2015;274(1):250–9.
NHS England. Service specification: specialised respiratory services (adult)—severe asthma. https://www.engage.england.nhs.uk/consultation/clinical-commissioning-wave4/user_uploads/drft-severe-asthma-serv-spec.pdf Accessed 13/11/2016.
Little SA, Sproule MW, Cowan MD, et al. High resolution computed tomographic assessment of airway wall thickness in chronic asthma: reproducibility and relationship with lung function and severity. Thorax. 2002;57:247–53.
Menzies D, Holmes L, McCumesky G, et al. Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma. Allergy. 2011;66(5):679–85.
Laxmanan B, Hogarth DK. Bronchial thermoplasty in asthma: current perspectives. J asthma allergy. 2015;8:39–49.
Jung JW, Kwon JW, Kim TW, et al. New insight into the assessment of asthma using xenon ventilation computed tomography. Ann Allergy Asthma Immunol. 2013;111(2):90–5.
Oostveen E, MacLeod D, Lorino H, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future development. Eur Resp J. 2003;22:1026–41.
McLaughlin RA, Noble PB, Sampson DD. Optical coherence tomography in respiratory science and medicine: from airways to alveoli. Physiology. 2014;29(5):369–80.
Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002;360(9347):1715–21.
Brightling CE, Green RH, Pavord ID. Biomarkers predicting response to corticosteroid therapy in asthma. Treatments Respir Med. 2005;4(5):309–16.
Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Resp Med. 2015;3(4):290–300.
Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. Cochrane DB Syst Rev. 2015;27(7):CD010834.
Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med. 2007;101(7):1483–92.
Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365(12):1088–98.
Chiappori A, De Ferrari L, Folli C, et al. Biomarkers and severe asthma: a critical appraisal. Clin Mol Allergy. 2015;13(20):1–11.
Gemicioglu B, Musellim B, Dogan I, et al. Fractional exhaled nitric oxide (FeNo) in different asthma phenotypes. Allergy Rhinol. 2014;5:e157–61.
Hanania NA, Wenzel S, Resén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Resp Crit Care Med. 2013;187(8):804–11.
Hanania NA, Korenblat P, Chapman KR, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781–96.
Vijverberg SJH, Hilvering B, Raaijmakers JAM, et al. Clinical utility of asthma biomarkers: from bench to bedside. Biol: Targets Ther. 2013;7:199–210.
Wang W, Li Y, Lv Z, et al. The Th2 cell-promoting cytokines IL-33 and TSLP, but not IL-25 are potential biomarkers for endotypes of asthma. Chest. 2016;149(4S):A34.
Miligkos M, Bannuru RR, Alkofide H, et al. Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med. 2015;163(10):756–67.
Mastalerz L, Nizankowska E, Sanak M, et al. Clinical and genetic features underlying the response of patients with bronchial asthma to treatment with a leukotriene receptor antagonist. Eur J Clin Investig. 2002;32(12):949–55.
Kane B, Fowler SJ, Niven RM. Refractory asthma—beyond step 5, the role of new and emerging adjuvant therapies. Chronic Resp Dis. 2015;12(1):69–77.
Kew KM, Undela K, Kotortsi I, et al. Macrolides for chronic asthma (review). Cochrane DB Syst Rev. 2015;9:CD002997.
Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017; In press. https://doi.org/10.1016/S0140-6736(17)31281-3.
Deeks ED. Mepolizumab: a review in eosinophilic asthma. Biodrugs. 2016;30(4):361–70.
Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockage in severe persistent asthma. Am J Resp Crit Care Med. 2009;179(7):549–58.
Bice JB, Leechawengwongs E, Montanaro A, et al. Biologic targeted therapy in asthma. Ann Allergy Asthma Immunol. 2014;112:108–15.
Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor α antagonist. J Allergy Clin Immunol. 2012;130(2):516–22.
Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an Anti-TSLP antibody on allergen-induced asthmatic response. N Engl J Med. 2014;370:2102–10.
Pretolani M, Bergqvist A, Thabut G, et al. Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: clinical and histopathological correlations. J Allergy Clin Immunol. 2016. doi:10.1016/j.jaci.2016.08.009.
Wechsler ME, Laviolette M, Rubin AS, et al. Bronchial thermoplasty: long-term safety and effectiveness in patients with severe persistent asthma. J Clin Immunol. 2013;132(6):1295–302.
Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008;32(3):545–54.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding was received for preparation of this manuscript.
Conflicts of interest
Katrina Dean reports no conflicts of interest. Robert Niven has received honorarium for speaker fees from AstraZeneca, Boehringer Ingelheim, Booston Scientific, Novartis, Napp, Teva and honorarium for advisory boards from AstraZeneca, Boehringer Ingelheim, Booston Scientific, Novartis, Teva and Vectura. RN has received support to attend international meetings from AstraZeneca, Boehringer Ingelheim, Cheisi and Novartis.
Rights and permissions
About this article
Cite this article
Dean, K., Niven, R. Asthma Phenotypes and Endotypes: Implications for Personalised Therapy. BioDrugs 31, 393–408 (2017). https://doi.org/10.1007/s40259-017-0242-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40259-017-0242-5